Surgery Websites
Pediatric Surgery »  Faculty »  Pediatric Surgeons »  Michael R. Harrison, M.D.

Michael R. Harrison, M.D.

Director Emeritus, Fetal Treatment Center
Division of Pediatric Surgery
Professor Emeritus of Surgery, Pediatrics, Obstetrics, Gynecology and Reproductive Sciences

Contact Information

Open Popup
  • 1961-65, Yale University, B.A.
  • 1965-69, Harvard Medical School, M.D., Medicine
  • 1969-71, Massachusetts General Hospital, Resident, Surgery
  • 1973-74, Massachusetts General Hospital, Senior Resident, Surgery
  • 1974-75, Massachusetts General Hospital, Chief Resident, Surgery
  • 1971-73, Laboratory of Immunology, National Institute of Allergy and Infectious Disease, Fellow, Allergy & Immunology (Peds)
  • 1975-76, Rikshospitalet, Fellow, Pediatric Surgery
  • 1976-78, Children's Hospital of Los Angeles, Fellow, Pediatric Surgery
  • American Board of Surgery, 1978, renewed 1988
  • American Board of Surgery, Special Competence in Pediatric Surgery, 1979, renewed 1989
  • American Board of Surgery, Surgical Critical Care, 1991
  • Fetal Treatment Center
  • Birth Defects
  • Congenital Diaphragmatic Hernia (CDH)
  • Fetal Surgery
  • Minimally Invasive Surgery
  • Pediatric Surgery
  • Developmental Biology
  • Hematopoietic Stem Cells
  • Pectus Excavatum Repair
  • World Health
  • Birth Defects
  • Minimally Invastive Surgery

Dr. Michael Harrison is Professor Emeritus of Surgery and Pediatrics and the Director Emeritus of the Fetal Treatment Center at UCSF. He graduated cum laude from Yale University and magna cum laude from Harvard Medical School. He completed his surgical training at the Massachusetts General Hospital in Boston and his pediatric surgery fellowship at Children's Hospital of Los Angeles. He is board certified in Surgery, Pediatric Surgery, and Critical Care.

Dr. Harrison and his surgery associates confine their surgical practice exclusively to children with special interest in fetal surgery, in repair of complex birth defects involving the chest, lung, abdomen, bowel, and bladder, and surgical care of children from birth through adolescence. Dr. Harrison and his associates, The Bay Area Pediatric Surgeons, do consultations and provide surgical care at Moffitt/Long Hospitals UCSF, California Pacific Medical Center, and Kaiser Permanente, San Francisco.

Dr. Harrison has a special interest in fetal surgery which he has pioneered with his colleagues at UCSF. For the past 18 years Dr. Harrison has studied the pathophysiology and natural history of a number of life-threatening fetal abnormalities including congenital diaphragmatic hernia, congenital cystic adenomatoid malformation of the lung, sacrococcygeal teratoma, fetal obstructive uropathy, and myelomeningocele. He has developed techniques for both in-utero open fetal surgery and endoscopic surgical repair (FETENDO Fetal Surgery)of many fetal abnormalities. In addition, Dr. Harrison's team has developed in-utero stem cell transplantation to treat immunodeficiencies, enzyme deficiencies, and hemoglobinopathies. Dr. Harrison leads the multidisciplinary UCSF Fetal Treatment Center Team that has developed an international reputation for treating complex birth defects before and after birth. (Referrals can be made to 1-800-RX-FETUS.)

Dr. Harrison, his wife Gretchen, and four children have lived in San Francisco for the past 20 years.

Data provided by UCSF Profiles, powered by CTSI
Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 485
Data provided by UCSF Profiles, powered by CTSI
  1. George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 Sep 09. View in PubMed
  2. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct; 20(10):1370-1385. View in PubMed
  3. Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med. 2019 Aug; 8(10):4644-4655. View in PubMed
  4. Ellison EC, Ponsky JL, Harrison MR, McGrath MH, Angelos P, Krummel TM. Presidential Forum. Ann Surg. 2019 10; 270(4):573-584. View in PubMed
  5. Winkler SM, Harrison MR, Messersmith PB. Biomaterials in fetal surgery. Biomater Sci. 2019 Aug 01; 7(8):3092-3109. View in PubMed
  6. View All Publications

 

Site Directory
    X